No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma
- PMID: 38697152
- DOI: 10.1016/S1470-2045(24)00197-9
No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma
Conflict of interest statement
I declare support for attending meetings and travel from Pfizer and Ipsen, and participation on an advisory board from Janssen and Astellas (fees paid to institution).
Comment on
-
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
